Study of HSK47977 for relapsed or refractory non-Hodgkin lymphoma
Part of Cancer clinical trials.
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-Hodgkin lymphoma that has returned or not responded to prior treatment.
- You are at least 18 years old.
- You have a tumor that can be measured on scans.
- You are willing and able to have a biopsy of your tumor tissue.
- Your overall health is reasonably good (able to do most daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-3079 for people with B-cell non-Hodgkin lymphoma whose cancer did not get better or came back after at least one standard treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
This Phase 1/2 study tests an injection called GNC-038 in people with non-Hodgkin’s lymphoma that has come back or is resistant to treatment. It aims to see how well the drug works and how safe it is for this group.
This trial tests a new drug, SHR2554, for people with follicular lymphoma that has returned or not responded to prior treatments. It aims to see if the drug can shrink tumors and slow the cancer's growth.
This trial tests a new drug, GNC-035, for people with non-Hodgkin's lymphoma that has come back (relapsed) or stopped responding to standard treatments (refractory). The goal is to see if GNC-035 can help when other options haven't worked.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
Hear when a new NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.